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SUMMARY
Severe fever with thrombocytopenia syndrome
virus (SFTSV) is a tick-borne virus with 12%–30%
casemortality rates and is related to the Heartland vi-
rus (HRTV) identified in the United States. Together,
SFTSV and HRTV are emerging segmented, nega-
tive-sense RNA viral (sNSV) pathogens with potential
global health impact. Here, we characterize the
amino-terminal cap-snatching endonuclease domain
of SFTSV polymerase (L) and solve a 2.4-A˚ X-ray crys-
tal structure. While the overall structure is similar to
those of other cap-snatching sNSV endonucleases,
differences near theC terminus of the SFTSV endonu-
clease suggest divergence in regulation. Influenza vi-
rus endonuclease inhibitors, including the US Food
and Drug Administration (FDA) approved Baloxavir
(BXA), inhibit the endonuclease activity in in vitro
enzymatic assays and in cell-based studies. BXA dis-
plays potent activity with a half maximal inhibitory
concentration (IC50) of 100 nM in enzyme inhibition
and an EC50 value of 250 nM against SFTSV and
HRTV in plaque assays. Together, our data support
sNSV endonucleases as an antiviral target.
INTRODUCTION
Severe fever with thrombocytopenia syndrome virus (SFTSV) is
an emerging pathogen that was initially discovered in China in
2009 (Yu et al., 2011) and has spread throughout East Asia,
including to Korea and Japan. SFTSV was isolated from patients
who presented with fever, thrombocytopenia, leukocytopenia,
and multiorgan failure (Chen et al., 2012; Yu et al., 2011; Zhang
et al., 2012a, 2012b). Ticks are the potential vector responsible
for the spread of SFTSV to humans, and among them, Haema-
physalis longicornis has been identified in the transmission of
the virus (Luo et al., 2015). Heartland virus (HRTV), a related
tick-borne virus, was found in the US in 2009 and infected indi-
viduals present with similar symptoms as SFTSV, highlighting
the widespread impact of banyangviruses to global human
health (McMullan et al., 2012). Currently, there are no US Food
and Drug Administration (FDA)-approved therapies or vaccines
available to counter bunyaviral infections. Most clinical treat-
ments are limited to therapeutic plasma exchange (Oh et al.,
2017) and supportive care. A standard nucleoside analog class
of inhibitors, such as ribavirin and favipiravir, has been tested
for antiviral activities against SFTSV and HRTV infections, as
they have been tested experimentally for other bunyaviral infec-
tions, including Hantaan virus (HTNV), Crimean Congo hemor-
rhagic fever virus (CCHFV), and Rift Valley Fever virus (RVFV)
(Beaucourt and Vignuzzi, 2014; Delang et al., 2018; Tani et al.,
2018;Westover et al., 2017). However, these nucleoside analogs
are clinically ineffective (Liu et al., 2013) and are associated with
adverse side effects. Plus many nucleotide analog inhibitors are
prone to the emergence of rapid resistant mutants. Ribavirin is
not recommended for clinical use owing to its high toxicity (Lu
et al., 2015; Russmann et al., 2006), and favipiravir possesses
a risk of teratogenicity and embryotoxicity (Furuta et al., 2017).
Thus, identification and characterization of antiviral targets
within SFTSV and HRTV will facilitate the discovery of previously
unrecognized opportunities to combat bunyaviral infections.
SFTSV is a segmented, negative-sense RNA virus (sNSV),
which includes viruses from the Bunyavirales and Articulavirales
orders. This virus is a member of the newly identified Banyangvi-
rus genus in the Phenuiviridae family of the Bunyavirales order
according to the Virus Taxonomy 2019, which is released by
the International Committee on Taxonomy of Viruses (ICTV)
(Abudurexiti et al., 2019). SFTSVs form spherical virions of
approximately 80–100 nm in diameter with viral glycoprotein
(Gn and Gc) at the membrane that facilitates entry (Lei et al.,
Cell Reports 30, 153–163, January 7, 2020 ª 2019 The Authors. 153
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2015; Yu et al., 2011). Inside the virion, the RNA genome is
composed into three segments (S, small; M, medium; and L,
large) that are encompassed by nucleoprotein and bound to L
polymerase. These segments encode for nucleoprotein (N) and
nonstructural protein (NSs), glycoprotein (Gn and Gc), and the
RNA-dependent RNA polymerase (RdRp or L), respectively (Lei
et al., 2015).
The bunyavirus L polymerase is required for viral replication
and transcription and it does not encode a domain with capping
activity. Instead, bunyaviruses employ the amino (N)-terminal
endonuclease domain of the L polymerase as a cap-snatching
mechanism that cannibalizes host cellular mRNA cap structures.
These short, capped RNA fragments then serve as primers for
viral mRNA transcription and allow for viral protein translation
(Reguera et al., 2010, 2016). Although this process has been
described extensively for influenza A virus (IAV) and to some de-
gree for other bunyaviruses (Amroun et al., 2017; Dias et al.,
2009; Duijsings et al., 2001; Garcin et al., 1995; Plotch et al.,
1981), less is known structurally and biochemically about the
SFTSV polymerase. Here, we report the identification of the
N-terminal endonuclease domain of the L polymerase of SFTSV,
which is crucial for cap-dependent viral mRNA transcription. We
solved the X-ray crystal structure of the endonuclease domain at
2.4-A˚ resolution, which revealed features that are unique to
SFTSV as well as those features that are shared among other
cap-snatching viral endonuclease domains (Ferna´ndez-Garcı´a
et al., 2016; Jones et al., 2019; Reguera et al., 2010, 2016;
Song et al., 2016). We also demonstrated the inhibition of SFTSV
and HRTV endonuclease activities by using IAV polymerase
acidic protein (PA) inhibitors, including Baloxavir acid (BXA)
derived from a recently FDA-approved drug, Baloxavir marboxil
(BXM), suggesting that the banyangvirus endonuclease domain
is a major therapeutic target that can guide the development of
broad-spectrum antivirals against sNSVs.
RESULTS
X-Ray Crystal Structure of the SFTSV L Endonuclease
Domain Reveals a Mixed Alpha-Beta Fold
While the domain organization of SFTSV polymerase remains
undefined, it is likely to be similar to other bunyaviruses (Ferna´n-
dez-Garcı´a et al., 2016; Gogrefe et al., 2019; Jones et al., 2019;
Reguera et al., 2016; Reguera et al., 2010), including Toscana vi-
rus (TOSV), Andes virus (ANDV), Lassa virus (LASV), La Crosse
virus (LACV), and RVFV, which contain an N-terminal endonu-
clease domain, a central RdRp domain, and a C-terminal cap-
binding domain (Figure S1A). SFTSV, HRTV, TOSV, ANDV,
LASV, LACV, and RVFV are genetically distinct and belong to
different bunyavirus families, while IAV is assigned to the Articu-
lavirales order (Figure S1B). Sequence alignment of the N-termi-
nal residues of several sNSVs suggests that SFTSV and HRTV
polymerases also include an N-terminal endonuclease domain
(Figure S1C). In order to biochemically characterize the SFTSV
endonuclease domain, we recombinantly expressed and puri-
fied the N terminus (1–231 aa) of SFTSV. Size exclusion chroma-
tography coupled to multi-angle light scattering (SEC-MALS)
analysis determined a molecular mass of 2.71 ± 0.01 3 104 Da
and the calculated protein molecular mass is 2.763 104 Da, sug-
gesting that the endonuclease domain is a monomer in solution
(Figure 1A).
We next initiated crystallization trials and obtained crystals
of SFTSV L 1–231 aa in the presence of trypsin. Analysis of
the mass of these crystals using liquid chromatography coupled
to mass spectrometry (LC-MS) identified three major protein
species: 1–226 aa (25143 Da), His-tagged (GSSHHHHHH
SSGLVPRGSH) 1–226 with the first methionine cleaved (26893
Da), and Met-His-tagged (MGSSHHHHHHSSGLVPRGSH)
1–226 (27,071 Da) (Figure S2). However, we were unable to solve
the structure of the SFTSV endonuclease domain by molecular
replacement using other endonuclease domain structures
(PDB: 5HSB, 5J1P, or 5DES) as search models. Therefore, we
generated selenomethionine (SeMet)-labeled protein crystals,
which grew in 0.1-M sodium citrate pH 5 and 10% polyethylene
glycol (PEG) 20,000, and built a lower-resolution (2.5 A˚) model
using a single-wavelength anomalous dispersion (SAD) phasing
method. This initial model was then used as the search model for
molecular replacement on another SeMet dataset with better
resolution and density to solve the X-ray crystal structure of
the SFTSV endonuclease domain to 2.4-A˚ resolution (Figure 1B).
The crystallographic asymmetric unit consists of three mole-
cules; however, we did not observe any significant buried sur-
face area that would indicate that the SFTSV endonuclease is
an oligomer. Furthermore, we only observed electron density
for residues 1–226, which corresponds to the 25,143-Da peak
A B Figure 1. The SFTSV L Endonuclease
Domain Is a Monomer in Solution and
Adopts a Mixed Alpha-Beta Fold
(A) SEC-MALS analysis of SFTSV L 1–231 aa. The
determined mass of SFTSV L 1–231 aa (green) is
2.71 ± 0.013 104 Da. The theoretical mass for the
monomer is 2.76 3 104 Da. Independent experi-
ments were carried out in triplicate and repre-
sentative data are shown here. Inset: Coomassie-
stained SDS-PAGE of purified, recombinant
N-terminal His-tagged SFTSV L endonuclease
domain 1–231 aa (arrowhead).
(B) X-ray crystal structure of the SFTSV L endo-
nuclease domain. Secondary structural elements
that form the a helices, the b sheets, and the loop
regions are annotated based on the relative posi-
tion from the N terminus.
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in our liquid chromatography-mass spectrometry (LC-MS) re-
sults (Figure S2). The overall structure features a central beta
sheet composed of sixmixed b strands (b1, b2, and b6-b9), form-
ing a twisted plane that is surrounded by six a helices (a1–a6)
and one 310-helix (h1). The two long parallel b7 and b8 strands
are connected by a long helix a4, which runs parallel to the cen-
tral b sheet and is flanked by a6 and h1. On the opposite side of
the b sheet, helix a5 is covered by a surface-exposed antiparallel
b sheet made of strands b3-b5. However, unlike other endonu-
clease domain structures, we did not observe any obvious den-
sity corresponding to a manganese ion in the active site even
though 5 mMmanganese chloride was supplied during crystalli-
zation. It is likely that themetal ions are chelated by the high con-
centration of sodium citrate in the crystallization buffer.
The Structural Fold of Endonuclease Domains from
sNSVs Is Largely Conserved
Analysis of the SFTSV endonuclease domain structure reveals
significant similarities to the cap-snatching endonucleases of
TOSV, ANDV, LASV, LACV, and IAV (Figures 2A and 2B). Struc-
tural alignments using the SuperPose tool (Krissinel and Henrick,
2004) show that all structures present root-mean-square devia-
tions (RMSDs) below 3.5 A˚ for at least 94 residues (Table S1)
despite having sequence identities below 20% (Figure S1C),
suggesting that the core regions are conserved among these en-
donucleases. Furthermore, the (H/E)-PD-(E/D)X-K motif critical
for the active site is conserved among these representative




Figure 2. The Structural Fold of sNSV Endo-
nuclease Domains Is Conserved among
sNSVs
(A) Comparisons of the endonuclease structures
of SFTSV (green, PDB: 6NTV), TOSV (purple, PDB:
6QW0), ANDV (blue, PDB: 5HSB), LASV (yellow,
PDB: 5J1P), LACV (cyan, PDB: 2XI5), and IAV
(orange, PDB: 5DES). Manganese ions are shown
as purple spheres in TOSV, ANDV, LASV, LACV,
and IAV structures. Key catalytic residues are
shown as sticks.
(B) Topological diagrams generated by TopDraw
of endonuclease domains shown in (A) with the
common core a helices represented as gray cyl-
inders and the b strands as white arrows. The
SFTSV L endonuclease domain contains a unique
b sheet insertion at the N terminus (red box) and an
extra C-terminal helix (black box).
(C) Close-up view of the active site of the SFTSV L
endonuclease domain. Key catalytic residues are
shown as sticks.
(D) Close-up view of superimposed endonuclease
structures of SFTSV (green), TOSV (purple), ANDV
(blue), and LASV (yellow). Key catalytic residues
are shown as sticks.
ture, residues H80, D112, and E126, cor-
responding to the divalent-cation binding
residues, and residue K145, correspond-
ing to the catalytic lysine, are oriented
with respect to each other (Figure 2C).
These highly conserved residues are positioned similarly in an
alignment with other endonuclease structures (Figure 2D). How-
ever, the SFTSV endonuclease contains an additional surface-
exposed beta sheet (strands b3-b5) that is positioned on top of
helix a5 (Figures 2A and 2B, red box outline). Only the recent
TOSV endonuclease structure (the PDB of which was released
while this manuscript was in review; PDB: 6QW0) (Jones et al.,
2019) contains a similar feature. Other endonuclease structures
lack this beta sheet entirely.
The N-Terminal Domains of Banyangviruses Show
Endonuclease Activity In Vitro
Several sNSV endonucleases require divalent metals for their
enzymatic activity (Doan et al., 1999; Ferna´ndez-Garcı´a et al.,
2016; Reguera et al., 2016). To assess the metal requirements
for SFTSV endonuclease activity, we first measured the stability
of SFTSV endonuclease in the absence and presence of divalent
cations (Mn2+, Mg2+, and Ca2+) using a fluorescence thermal-shift
assay (TSA) (Figure 3A). We found that SFTSV endonuclease dis-
played amelting temperature (Tm) of 51.8
C in the absence of any
metal ions. Addition of Mn2+ increased the thermal stability of
SFTSV endonuclease to 54.2C, whereas addition of Mg2+ or
Ca2+ had no measurable difference in the thermal stability, sug-
gesting that SFTSV endonuclease binds Mn2+ ions. Native MS
supports this as two species were identified. One that bound
one Mn2+ ion and a second that bound twoMn2+ ions (Figure 3B).
To further assess the functional implications, we used a fluores-
cence resonance energy transfer (FRET)-based endonuclease
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assay to measure the dependence of Mn2+ binding on endonu-
clease activity. Mn2+ binding correlated with data from a FRET-
based endonuclease assay using different metal ions (Figure S3).
These results further support that SFTSV, and likely HRTV, endo-
nuclease utilizes Mn2+ as a co-factor for its enzymatic activity. To
determine the optimal concentration of endonuclease protein for
FRET-based endonuclease assays, we tested different concen-
trations of protein ranging from 0.125 to 2 mM (Figure 3C), which
identified 1 mMas the best concentration with the largest dynamic
range. Next, we used the enzymatic assay to characterize the
following SFTSV endonuclease mutants: H80A, D92A, D112A, or
E126A. As these residues are important for either metal binding
or for catalytic activity based on structural homology (Figure 2C),
thesemutants displayed a dramatic reduction in the enzymatic re-
action rate (Figure 3D). Specifically, the D112A mutant showed
near-complete loss of SFTSV endonuclease activity, whereas
H80A, D92A, and E126A mutants displayed drastically reduced
endonuclease activity (Figure 3D). These observations indicate
that despite relatively low sequence similarities among the SFTSV
L 1-231 aa, HRTV L 1-231 aa, and IAV PA 1-192 aa endonuclease
domains, they contain the same key amino acid residues within
their enzyme pockets and kinetic properties that suggest similar
functions.
Structural Elements Unique to SFTSV L Endonuclease
Modulate Its Activity
In our X-ray crystal structure, we observed two structural
elements that are unique to the SFTSV endonuclease domain,
which are absent in the previously solved endonuclease do-
mains. The first element is a beta sheet ‘‘cap’’ that sits on top
of the endonuclease domain (Figure 2A, red box), which is an
insertion that is absent in other endonucleases from this family.
The TOSV endonuclease structure shares this feature, but its
exact role in endonuclease activity has not been described
thus far. Our attempts to evaluate the function of this domain
led to the generation of several N-terminal truncation mutations.
Not surprisingly, the N-terminal deletion mutations containing
residues 22–231 aa or 75–231 aa resulted in a destabilized
SFTSV L protein. Importantly, the b1 secondary structure
element is part of the mixed alpha-beta structure. Given the
structural importance of the beta ‘‘cap’’ to the structure, it is
tempting to speculate that the cap may be important for
protein-protein interactions, a notion supported by a prediction
algorithm (Figure S4). These observations require future experi-
mental validation.
Next, we explored the significance of the additional structural
element, helix a6, at the C terminus of the endonuclease domain
(Figure 2A, black box). In the structure, it appears that the C-ter-
minal a6 helix sits on the active site, likely to occlude access to
substrates and that may undergo substantial dynamics to enable
substrate to reach the active site. To test this hypothesis, we first
performed a molecular dynamics simulation of the SFTSV endo-
nuclease crystal structure. The Markov state models were built
from the fluctuation amplification of specific traits (FAST) simula-
tion data, and the solvent accessible surface area (SASA) of each
residue was averaged with the preceding and subsequent
A B
C D
Figure 3. The SFTSV L Endonuclease Activ-
ity Is Sensitive to Divalent Cations
(A) Thermal stability of SFTSV L 1–231 aa protein
in the absence or presence of 2-mM divalent
cations. No divalent cations, blue; manganese
(Mn2+), red; magnesium (Mg2+), cyan; and cal-
cium (Ca2+), magenta. The lines represent the
non-linear fits of the normalized fluorescence
curves to the Boltzmann equation.
(B) Intact mass measurement of SFTSV L 1–231
aa protein using LC-MS. Native mass spectra of
SFTSV L 1–231 aa (black) and SFTSV L 1–231 aa
with MnCl2 (red) from charge state +9 are shown.
27,637, 27,691 and 27,744 Da are masses that
represent SFTSV L residues 1–231 with first
methionine modified (+46 Da) His6-tag, plus 0, 1,
or 2 Mn2+. 27,460, 27,513 and 27,568 are masses
that represent SFTSV L residues 1–231 with first
methionine cleaved His6-tag, plus 0, 1, or 2 Mn
2+.
(C) FRET-based endonuclease activity of
SFTSV L 1–231 aa was measured by monitoring
fluorescence intensity using lex/lem = 485 nm/
535 nm. Increasing concentrations of SFTSV L
1–231 aa (2 mM, blue; 1 mM, magenta; 0.5 mM,
cyan; 0.25 mM, orange; 0.125 mM, dark brown)
were incubated with a 100-nM single-stranded
RNA (ssRNA) probe. Buffer only (black)
and substrate only (red) were included as blank
and background controls, respectively. Each data
point represents the average of three independent runs with error bars representing the standard deviation, which was then fit using a four-parameter log curve.
(D) Active sitemutations severely impair SFTSVendonuclease activity. FRET-based endonuclease assayswere performed in the presence of 1-mMSFTSVwild-type
(red) or SFTSVmutants (H80A, blue; D92A, dark brown; D112A, magenta; E126A, orange). Buffer only (black) and substrate only (cyan) were included as blank and
background controls, respectively. Experiments were carried out in triplicate and average data are shown with error bars representing the standard deviation.
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residue to highlight concerted behaviors (Figures 4A and 4B).
Our results predict that the C-terminal a6 helix is highly flexible.
Specifically, we observed significant clusters of structures with
varying radii of gyration (Figure 4A). Importantly, residues near
the a6 helix displayed the largest change in SASA (Figure 4B).
To complement the static X-ray structure and the computational
simulation studies, we performed hydrogen deuterium exchange
mass spectrometry (HDX-MS) experiments to assess the
dynamics of the protein. The results showed that the SFTSV
endonuclease domain, based on exchange behavior, could be
classified into four regions by its HDX kinetics (Figures 4C and
S5). The first region (blue), composed of b7 and 8 of the center
beta sheet and parts of a4 and a5, undergoesminimal deuterium
exchange at 10 s and does not increase significantly with time.
This first region makes up a rigid core that is highly structured
and protected. An exception is that Leu87, Ser88, and Lys89
also show high levels of exchange across the HDX time range.
These residues form a dynamic loop that stands out from the
nearby core region. The second region (dark green), which in-
cludes residues from a1, a3, h1, and b6, as well as the loops
associated with these elements, has slightly faster exchange
from a low percentage of exchange at early times, indicating
this region is also highly structured but slightly less rigid. Region
2 plus the previous rigid core surrounds and sandwiches the
active site of SFTSV L protein. The third region (green) contains
a2 and the first several residues of a4 and b1-b5. This group
shows initial exchange rates between 10% and 20%. This region
displays a more noticeable rapid increase than the previous two
regions and displays exchange rates of 60%–80%. The third re-
gion also surrounds the C terminus of the endonuclease domain.
The fourth region (orange) contains the last few residues of a5,
a6, and a few C-terminal residues that lack electron density in
our crystal structure. This is the most dynamic region, where




Figure 4. Conformational Dynamics C-Terminal a6 Helix of SFTSV L Protein Modulates Its Endonuclease Activity
(A) Dynamic simulation of SFTSV L 1–231 aa. The C-terminal a6 helix (colored in blue) is predicted to be very flexible.
(B) The average solvent accessible surface area (SASA) of each residue in SFTSV L 1–231 aa.
(C) Deuterium uptake in SFTSV L 1–231 aa fromHDX-MS. The deuterium uptake on SFTSV L 1–231 aa is mapped onto its sequence and secondary structure with
color for exchange time at 120 s of exposure in a D2O buffer (Figure S5). Groups of residues with similar differential deuterium exchange rates are colored
according to a gradient for HDX-MS rates in Figure S5.
(D) FRET-based endonuclease assays of SFTSV L 1–231 aa (black) and SFTSV L 1–208 aa (red). Experiments were carried out in triplicate and average data are
shown with error bars representing the standard deviation.
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observation is suggestive of rapid breathingmotions, likely of the
a6 helix at a time shorter than we can achieve in our HDX-MS
experiment (i.e., exchangewithin the ‘‘dead’’ time, prior to detec-
tion, which is about 10 ms). In this fourth region, exchange rates
rapidly increase to 80%–100% at 900 s. These results offer
experimental confirmation that the fourth region, which contains
a6, is highly dynamic and likely serves as a hinge and cap for the
active site. Given the proximity of the third region to the hinge, its
increased dynamics can be caused by opening and closing of
the a6 helix. To further determine the role of the C-terminal a6 he-
lix in the catalytic activity, we compared the endonuclease activ-
ities of wild-type (1–231 aa) and a C-terminal deletion mutant
(1–208 aa) using a FRET-based assay (Figure 4D). The C-termi-
nal deletion mutant (1–208 aa) showed higher endonuclease ac-
tivity than did the wild-type (1–231 aa). Collectively, results from
the FRET assay and HDX-MS studies closely mirror the molecu-
lar dynamics results, suggesting that our data are internally
consistent and support a model where the C-terminal helix a6
structurally regulates endonuclease activity by controlling ac-
cess to the active site.
Cap-Snatching Endonucleases Are Antiviral Targets
Drug repurposing can offer faster drug discovery and shorter
development times with reduced risk than de novo drug
discovery and development strategies (Ashburn and Thor,
2004). To test the potential use of SFTSV and HRTV endonu-
clease domains as antiviral targets, we tested the efficacy of
several influenza endonuclease inhibitors on SFTSV and HRTV
endonuclease domains. Our studies included the recently
FDA-approved compound BXM (Omoto et al., 2018), which is
a prodrug that is converted to its active acidic form BXA. Using
an in vitro FRET-based assay, we found that BXA effectively in-
hibited the enzymatic activity of SFTSV L, HRTV L, and IAV PA
endonucleases with half maximal inhibitory concentration (IC50)
values of 135 ± 5, 116 ± 2, and 36 ± 3 nM, respectively
(Table S2; Figure 5A). By comparison, L-742,001 (Song et al.,
2016) inhibited with IC50 values of 2.1 ± 0.2, 3.3 ± 0.4, and 1.4
± 0.1 mM, respectively (Table S2; Figure S6A). Corresponding vi-
rus growth inhibition assay revealed that BXA suppressed
SFTSV and HRTV replication at a concentration above 250 nM,
whereas L-742,001 only worked at high concentrations
(>50 mM) (Figures 5C, 5D, S6B, and S6C). Similarly, BXA inhibited
SFTSV and HRTV plaque formation with half maximal effective
concentration (EC50) values of 263 ± 14 and 248 ± 5 nM, respec-
tively (Figure 5B), whereas L-742,001 failed to inhibit plaque for-
mation (data not shown). To further verify direct binding between
the inhibitor and endonuclease domains, we conducted TSA ex-
periments. These results revealed that the addition of 2mMMn2+
and 200 mM BXA increased the thermostability by
10.5C,12.5C, and 28.1C for SFTSV, HRTV, and IAV endonu-
cleases, respectively, compared to each protein with only
Mn2+ added (Figures 6A–6C). These TSA results also suggest
that BXA stabilizes the SFTSV and HRTV endonucleases in a
Mn2+-dependent manner similar to IAV with approximately
2-fold lower stabilization of SFTSV and HRTV relative to IAV.
While BXA has been shown to chelate the two metal ions in the
active site of IAV and IBV endonucleases (Omoto et al., 2018),
we currently lack direct structural evidence for SFTSV or HRTV
A B
C D
Figure 5. Characterization of SFTSV L
Endonuclease Inhibitors
(A) FRET-based assays with SFTSV L 1–231 aa
(black), HRTV L 1–231 aa (red), or IAV PA 1–192 aa
(blue) in the presence of 1 mM MnCl2 and
increasing concentrations of BXA. The dose-
response curves were fit to yield IC50 values using
a nonlinear regression model. Experiments were
carried out in triplicate and average data are
shown with error bars representing the standard
deviation.
(B) Plaque reduction assays for SFTSV (black) and
HRTV (red). Plaques were counted by visual ex-
amination and the required concentration to
reduce the 50% plaque number (EC50) was
calculated as relative to the control without BXA.
Experiments were carried out in duplicate and
average data are shown with error bars repre-
senting the standard deviation.
(C and D) Virus growth inhibition assays of (C)
SFTSV or (D) HRTV in the presence of BXA. BXA
concentrations used are as follows: 1000 nM,
square; 500 nM, diamond; 250 nM, hexagon;
125 nM, down triangle; 62.5 nM, cross; and 0 nM,
star. The virus yield was visualized by immuno-
staining and expressed as TCID50/mL using the
Reed-Muench method. Experiments were carried
out in duplicate.
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endonuclease interactions with BXA or L-742,001. To further
probe the binding mode between SFTSV and HRTV endonu-
clease and BXA and L-742,001 inhibitors, we used Surfelx-
dock to dock the small molecules into the endonuclease active
site (H80, D112, E126, F127, S128, K145, E219, and A223). Ex-
amination of the best poses, shown in Figure 6D (left) and Fig-
ure S6D, suggests that both compounds bind in amanner similar
to that of influenza virus endonuclease (Figure 6D, right). Taken
together, our data show that BXA and L-742,001 bind and stabi-
lize SFTSV and HRTV endonuclease domains and that the bind-
ing results in inhibition of enzymatic activity. These studies also
support the broad-spectrum efficacy of these endonuclease
inhibitors.
DISCUSSION
Bunyavirus L polymerases are composed of a single polypeptide
protein containing multiple functions, including an N-terminal
endonuclease that is important for cleaving host pre-mRNAs
required for viral transcription to proceed (Gerlach et al., 2015).
While much of what is known about the sNSV cap-snatching
mechanism is largely derived from studies of the IAV polymerase
complex (Hengrung et al., 2015; Pflug et al., 2014; Reich et al.,
2014; Thierry et al., 2016;Walker and Fodor, 2019), less is known
mechanistically regarding bunyavirus polymerases. Here, we
present the 2.4-A˚-resolution X-ray crystal structure and func-
tional characterization of the SFTSV endonuclease. We find
that the SFTSV endonuclease adopts a mixed alpha-beta fold
and contains a (H/E)-PD-(E/D)X-K motif that is similar to other
viral endonucleases, including TOSV L (Jones et al., 2019), IAV
PA (Song et al., 2016), LACV L (Reguera et al., 2010), LASV L
(Reguera et al., 2016), and ANDV L (Ferna´ndez-Garcı´a et al.,
2016). Closer examination of the structures reveals that the
active site of the SFTSV endonuclease domain is more closely
related to the ANDV and LASV endonuclease domains as it fea-
tures a cluster of three acidic residues (D92, D112, and E126), a
lysine residue (K145) neighboring E126, and a histidine residue
(H80). Mutation of these residues dramatically reduced SFTSV
endonuclease activity. Furthermore, mutation of D112 resulted
in the largest reduction of endonuclease activity, likely due to co-
ordination of the twomanganese ions by D112, which are impor-
tant for the stability of the endonuclease. We also proved the
binding by native MS that SFTSV endonuclease could bind to
one or two Mn2+. While in TOSV, without inhibitor only one
Mn2+ is chelated rather than two dues to the flexibility of the
loop, which D90 locates (Jones et al., 2019). Further experiments




Figure 6. Inhibitor Binding to SFTSV L Endonuclease Stabilizes Its Endonuclease Domain
(A–C) Thermal stability was measured in the presence of 10 mM EGTA for (A) SFTSV L 1–231 aa (black), (B) HRTV L 1–231 aa (red), or (C) IAV PA 1–192 aa (blue).
Thermal stability for each viral endonuclease was also measured in the presence of 2 mM MnCl2 (orange) and 2 mM MnCl2 with 0.2 mM BXA (cyan). The lines
represent the non-linear fits of the normalized fluorescence curves to Boltzmann equation.
(D) Left: docking simulation of two manganese ions (purple) and BXA (yellow) with SFTSV L 1–231 aa (green). Key residues are shown in stick representation.
Right: structure of BXA bound to IAV PA (PDB: 6FS6) is shown for comparison.
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Interestingly, the SFTSV endonuclease contains an addi-
tional surface-exposed, anti-parallel b sheet (b3-b5) that is
orthogonal to the central b sheet and covers helix a5. This
structural element is unique to the banyangviruses and phlebo-
viruses, but absent in other sNSV endonuclease structures.
Truncation of this element resulted in a destabilized protein
(75–231 aa; data not shown), suggesting that the b sheet and
the N-terminal region are important for the stability of the
SFTSV endonuclease domain. Moreover, analysis using cons-
PPISP, a 3D-structure-based protein-protein interaction pre-
dictor (Chen and Zhou, 2005) to predict the residues that will
likely form the binding site for another protein, suggests that
the neutral/acidic residues (T39, D41, T46, D48, G50, A51,
V52, D54, S55, S62, I63, N64, A65, G66, L67, I68, T69, I70,
Q71, and E74) located within the b sheet may be associated
with protein-protein interaction (Figures S4A and S4B). While
this manuscript was in preparation, Jones et al. (2019) pub-
lished the endonuclease structure from TOSV, which also con-
tains an anti-parallel b sheet capping helix a5. However, the
TOSV endonuclease, as well as other viral endonuclease struc-
tures available to date, are lacking the C-terminal helix a6 that is
unique to the SFTSV endonuclease structure. Our analysis of
the functional significance revealed that helix a6 plays a critical
role in modulating endonuclease activity. Specifically, deletion
of helix a6 increased SFTSV endonuclease activity. Consistent
with this observation, molecular dynamic simulations show a
high degree of flexibility and conformational heterogeneity of
helix a6. Our in vitro experimental attempts to test the dynamic
nature of helix a6 and its potential role in the regulation of
enzyme activity by HDX-MS further support the notion that
the dynamics of helix a6 likely control substrate accessibility
and endonuclease function in SFTSV and HRTV. Further
studies are warranted to determine if similar regulatory ele-
ments exist at the C-termini of other viral endonucleases.
The metal binding properties of viral endonucleases provide
considerable opportunities for the repurposing of FDA-approved
drugs and candidates (Credille et al., 2018; Omoto et al., 2018).
Previously, a number of inhibitors that target the IAV PA endonu-
clease domain have been characterized (Ju et al., 2017). Our
initial studies reveal that SFTSV endonuclease is also inhibited
by these inhibitors, albeit less effectively. In 2018, the FDA
approved Baloxavir Marboxil, a prodrug that is represented by
its active form BXA. Based upon available data, including struc-
tural studies, BXA binds the IAV endonuclease active site near
two Mn2+ ions and this binding inhibits cleavage of a pre-
mRNA substrate at the 30 end of guanine (Omoto et al., 2018).
This mechanism of inhibition is similar to dolutegravir, a BXA
analog that inhibits human immunodeficiency virus (HIV)
integrase (Johns et al., 2013). Our study reveals that BXA can
effectively inhibit SFTSV and HRTV endonuclease activities,
further supporting the broad utility of BXA as an antiviral agent
against sNSV endonucleases. In addition to demonstrating the
application of drug repurposing for endonucleases, our studies
demonstrate the generality of metal chelating small molecules
as specific inhibitors of microbial enzymes. While our data
strongly support the potential use of BXM to treat SFTSV and
SRTV infections, future studies are needed to assess the efficacy
in in vivo models.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, Alexa Fluor 488
Thermo Fisher Scientific Cat#A-11001; RRID:AB_2534069
Polyclonal serum to SFTSV NP (Anti-NP) Wenhui Li (National Institute of
Biological Sciences)
N/A
Monoclonal anti-HRTV NP (2AG8) Amanda E. Calvert (U.S. Centers for
Disease Control and Prevention)
N/A
Bacterial and Virus Strains
Severe Fever with Thrombocytopenia Syndrome virus
(SFTSV) or Huaiyangshan banyangvirus
Brennan et al., 2015 N/A
Heartland virus BEI Resources NR-49771
Escherichia coli BL21(DE3) Novagen Cat#69450
Biological Samples
Fetal Bovine serum (GIBCO) Thermo Fisher Scientific Cat#16140071
Chemicals, Peptides, and Recombinant Proteins
L-742,001 Sigma-Aldrich Cat#SML1010-5MG
Baloxavir acid Probechem Cat#PC-35417-5MG
Sypro Orange Invitrogen Cat#S6650
TALON Metal Affinity Resin Takara Cat#635504
TransIT-LT1 Mirus Bio Cat#MIR2300
Trypsin Hampton Research Cat#HR2-429-02
Deposited Data
Structure of SFTSV L endonuclease domain This paper PDB: 6NTV
Experimental Models: Cell Lines
Vero E6 ATCC Cat#CRL-1586; RRID:CVCL_0574






pRev (T7 RNA polymerase expressing plasmid) Julie Pfeiffer (The University of Texas
Southwestern Medical Center)
N/A
pTM-L Brennan et al., 2015 N/A
pTM-N Brennan et al., 2015 N/A
pTVT-L Brennan et al., 2015 N/A
pTVT-M Brennan et al., 2015 N/A
pTVT-S Brennan et al., 2015 N/A
SFTSV L 1-231aa This paper N/A
HRTV L 1-231aa This paper N/A
IAV L 1-192aa DuBois et al., 2012 N/A
Software and Algorithms
HKL3000 Minor et al., 2006 https://hkl-xray.com/hkl-3000
CCP4i Winn et al., 2011 https://www.ccp4.ac.uk/ccp4i_main.php
Phenix Adams et al., 2010 https://www.phenix-online.org/
WinCoot Emsley et al., 2010 http://bernhardcl.github.io/coot/
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Gaya K.
Amarasinghe (gamarasinghe@wustl.edu). All unique/stable reagents generated in this study are available from the Lead Contact with
a completed Materials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial Cultures
For recombinant protein expression, we used the Escherichia coli strain BL21(DE3) (Novagen). Cells were grown at 37C as
described in the Method Details section.
Cells and Viruses
Vero E6 cells and 293-T cells were purchased from ATCC and maintained in Dulbecco’s modified Eagle’s medium (Thermo Fisher
Scientific, #11965118) containing 10%Fetal Bovine Serum (VWR Life Science Seradigm, #1500-500) and 1%penicillin-streptomycin
(Thermo Fisher Scientific, #15140163). Transient transfections for virus rescue were performed with polyethylenimine (PEI) transfec-
tion reagent (Polysciences, #23966) according to the manufacturer’s instructions.
For SFTSV generation, 293-T cells were co-transfected with plasmid expressing T7 polymerase along with plasmids for SFTSV
reverse genetics (pTM-ppL, pTM-N, pTVT-ppL, pTVT-ppM and pTVT-S) (Brennan et al., 2015) with PEI at 3:1 ratio. After 5 days
post-transfection, the supernatant was collected and passed through a 0.2 mM polyethersulfone (PES) filter (Nalgene, #566-0020).
The clarified supernatant was loaded into Vero cells and supernatant was collected after 9 days post-infection. After the supernatant
was clarified, the virus suspension was aliquoted and stored at80C until use. For HRTV, virus was purchased from BEI Resources
(https://www.beiresources.org/) with one passage in Vero E6 cells and the supernatant was aliquoted and stored at80C until use.
METHOD DETAILS
Compounds
All the compounds used in this study were purchased from a commercial vendor. Briefly, L-742,001 was purchased from Sigma-Al-
drich (#SML1010-5MG) and Baloxavir acid (S-033447, BXA) was purchased from Probechem (#PC-35417-5MG).
Plasmids
The SFTSV (GenBank Accession AFK08658.1) 1-231 aa, HRTV L (GenBank Accession AIF75093.1) 1-231 aa and IAV PA (DuBois
et al., 2012) 1-192 aa were synthesized (Genewiz) and subclones into a pET52b(+) expression vector between 50 NcoI and 30 NotI
sites for expression in E. Coli. Mutant constructs were generated using GeneArt Site-Directed Mutagenesis System (Thermo Fisher
Scientific, #A13282) according to the manufacturer’s instructions.
Protein Expression and Purification
Plasmids encoding SFTSV L 1-231 aa, HRTV L 1-231 aa, and IAV PA 1-192 aa were transformed in BL21(DE3) E. coli cells (Novagen),
cultured in Luria Brothmedia or inM9medium (for selenomethionine labeled proteins) at 37C, inducedwith 0.5 mM IPTG, and grown
for 12 hr at 15C. Cells were harvested and resuspended in lysis buffer containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Pymol 2.3 Schro¨dinger https://pymol.org/2/
ASTRA 6 Wyatt https://www.wyatt.com/products/software/
astra.html
Origin 7 OriginLab https://www.originlab.com/
Prism 7 GraphPad Software https://www.graphpad.com/scientific-
software/prism/
MagTran Zhang and Marshall, 1998 N/A
Byonic and Byologic Protein Metrics https://www.proteinmetrics.com/
HDExaminer Sierra Analytics http://massspec.com/hdexaminer/
Gromacs 5.1.1 Abraham et al., 2015 http://manual.gromacs.org/5.1.1/index.html
FAST algorithm Zimmerman and Bowman, 2015, 2016 N/A
Surflex-dock Jain, 2007 https://omictools.com/surflex-dock-tool
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imidazole, 5mM 2-mercaptoethanol, andwere lysed using an EmulsiFlex-C5 homogenizer (Avestin). Lysates were clarified by centri-
fugation at 47,000 x g at 4C for 40 min. Proteins were purified using a series of chromatographic columns and a size exclusion col-
umn as a final step. Protein purity was determined by Coomassie staining of SDS-PAGE.
SEC-MALS
SEC-MALS experiments were performed using a DAWN-HELEOS II detector (Wyatt Technologies) coupled to a Superdex 200 In-
crease 10/300 column (GE Healthcare) in 20 mM HEPES pH 7, 150 mM NaCl. 2 mg/ml protein was injected, and raw data were
analyzed using ASTRA 6 software (Wyatt Technologies) to determine the weight averaged molecular mass (MW). Protein concentra-
tions were determined using the refractive index measured by an Optilab T-rEX (Wyatt Technologies) and a dn/dc of 0.174 mL3 gd.
Protein Crystallization
The initial crystallization condition was obtained by sparse matrix screening with Hampton Research screens using the vapor diffu-
sion method in sitting drop mode. In some conditions, 10 mg/ml of SFTSV L 1-231 aa was mixed with trypsin in a 1:1,000 ratio. From
the initial primary screens, we observed about 10 conditions in which protein crystals appeared within 7-12 days of setting up at
20 C. Similar conditions were obtained for SeMet labeled SFTSV L protein construct 1-231 aa. The crystal from which the structure
was solved came from the following growth condition: 0.1 M sodium citrate pH 5 and 10% PEG 20,000. Crystals appeared after
1 week at 20C and were vitrified in a solution containing the mother liquor plus 25% PEG400.
Proteins in the crystals were analyzed by liquid chromatography-mass spectrometry (LC-MS) to identify their molecular weight
before Se-Met incorporation. 10 protein crystals were picked up, washed with well solution, and subsequently dissolved in 10 mL
water. 1 mL sample was then diluted in 50 mL 0.1% formic acid and injected into a two-valve LC device. The proteins were captured
on a ZORBAX Eclipse XDB C8 column (2.13 15 mm, Agilent) for desalting (3 min) with 0.1% trifluoroacetic acid. The C8 column was
then switched inline. A linear gradient (3% to 80% acetonitrile, 0.1% formic acid, 200 mL/min flow rate, over 5 min) was used to elute
proteins subjected to electrospray ionization source equipped on aMaxis 4GQ-TOFmass spectrometer (Bruker). Mass spectra were
deconvoluted with MagTran (Zhang and Marshall, 1998) to give zero-charge intact mass of proteins. The intact mass was used to
match the SFTSV L sequence.
Data Collection and Structure Determination
Crystals were screened at Advanced Photon Source Beamline 19ID at the Argonne National Laboratory. Diffraction images were pro-
cessed by HKL3000 (Minor et al., 2006). The initial model was determined by the single-wavelength anomalous diffraction phasing
method from a single Se-Met substituted protein crystal to a maximum resolution of 2.50 A˚. The SHELX C/D/E pipeline (Sheldrick,
2008) in CCP4i (Winn et al., 2011) was used to locate the selenium atoms and perform phasing. Then AutoSol (Terwilliger et al., 2009)
in Phenix (Adams et al., 2010) was used to improve the experimental phasing and build initial model. Automated model-building and
refinement was carried out using AutoBuild (Terwilliger et al., 2008) as implemented in Phenix. The initial model was used as the
search model against another Se-Met dataset and solved to 2.40 A˚ resolution by molecular replacement using the Molrep program
(Vagin and Teplyakov, 2010) as part of the CCP4i program suite. SFTSV L 1-226 residues were built by manual building in COOT
(Emsley et al., 2010) and refined with Refmac5 (Murshudov et al., 1997) and Phenix.refine (Afonine et al., 2012). The structure quality
was assessed byMolProbity (Chen et al., 2010). Data collection and refinement statistics are listed in Table S3. Structure figures were
prepared using PyMOL (Schrodinger, 2018).
Sequences Alignment and Graphical Presentation
Alignment of the endonuclease domain of Severe fever with thrombocytopenia virus (SFTSV; GenBank Accession code AFK08658.1)
with Heartland virus [Heartland virus (HRTV; GenBank Accession AIF75093.1), Toscana virus (TOSV; GenBank Accession
ALS19628.1), Lassa mammarenavirus (LASV; GenBank Accession AAT48998.1), Andes orthohantavirus (ANDV; GenBank Accession
NP_604473.1), Influenza A virus (A/H1N1; UniProtKB C3W5S0), Uukuniemi virus (UUKV; GenBank Accession NP_941973.1), Seoul
orthohantavirus (SEOV; GenBank Accession NP_942558.1), Sin Nombre orthohantavirus (SNV; GenBank Accession NP_941976.1)
and La Crosse virus (LACV; GenBank Accession ADH04736.1)]. The alignment was generated using Expresso software (Armougom
et al., 2006; Di Tommaso et al., 2011), taking into account available structural information (PDB code 6NTV for SFTSV, 6QW5 for
TOSV, 5J1P for LASV, 2XI5 for LACV, 5HSB for ANDV, 5IZE for SOEV, and 5W3I for IAV) and visualized using ESPript 3.0 (Robert
and Gouet, 2014). Red triangles highlight the H/E-PD-E/DX-K motif in the active site.
Thermal Shift Assays (TSA)
The thermal stability of SFTSV L 1-231 aa, HRTV L 1-231 aa, and IAV PA 1-192 aa proteins were measured by TSA. The assay con-
tained a final concentration of 5 mM protein (SFTSV 1-231 aa, HRTV L 1-231 aa, or IAV PA 1-192 aa), 4.5 3 Sypro Orange, 20 mM
HEPES pH 7.8, 150 mM NaCl, supplemented with either 2 mM MnCl2, 2 mM MgCl2, 2 mM CaCl2, 2 mM MnCl2 plus 200 mM BXA,
10 mM EGTA, or 10 mM EGTA plus 200 mM BXA as described previously (Ericsson et al., 2006). The plates were heated in
StepOnePlus Real-Time PCR System (Thermo Fisher) from 20 to 90C in increments of 0.3C. The wavelengths for excitation and
emission were 490 and 575 nm, respectively.
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Endonuclease Assay
Enzymatic activity of purifiedN-terminal region of SFTSVandHRTVLwasmeasured byusing FRET-based endonuclease assaywith a
little modification of previously reported publication (Noble et al., 2012). Briefly, recombinant amino-terminal protein of L segment of
either SFTSVorHRTV (1mM)wasmixedwith a 100nMsingle strandedRNA (ssRNA) probe (5’ FAM-AGGAAGAUUAAUAAUUUUCCU-
IowaBlack FQ3’) in reaction buffer containing 50mMHEPESpH7.8, 150mMKCl and 1mMMnCl2 (unless indicated otherwise). The
reactions were measured by detecting fluorescence intensity (lex/lem = 485nm/535nm) using FilterMax F5 Multi-Mode Microplate
Reader (Molecular Devices, LLC). To measure the enzyme kinetics, the reactions were measured every 5 min until reactions were
saturated. In case of endonuclease inhibition assay, inhibitors were added at the indicated concentrations and an IC50 value was
determined using a linear regressionmodel. All assays performed at least in triplicate using at least two different protein preparations.
Hydrogen Deuterium Exchange Mass Spectrometry
SFTSV L 1-231 aa sample was buffer exchanged with 1 3 PBS pH 7.4. HDX was initiated by diluting samples (25 mM, 2 mL) 10-fold
with 13 PBS prepared in D2O, or 13 PBS H2O buffer for samples measured for no-deuterium control. At different time intervals (10,
30, 60, 120, 900, 3,600, and 14,400 s), the exchange reaction was quenched by rapidly decreasing the pH to 2.5 with 30 mL of quench
buffer (3 M urea, 1% trifluoroacetic acid, H2O) at 4
C. The protein mixture was immediately injected into a custom-built HDX sample-
handling device that enabled on-column digestion with resin-immobilized pepsin (2 3 20 mm) at a flow rate of 100 mL/min in 0.1%
trifluoroacetic acid. The resulting peptic peptides were captured on a ZORBAX Eclipse XDB C8 column (2.1 3 15 mm, Agilent) for
desalting (3 min). The C8 column was then switched inline, followed by a Hypersil Gold C18 column (2.1 mm3 50mm, Thermo Fisher
Scientific). A linear gradient (4%–40% acetonitrile, 0.1% formic acid, 50 mL/min flow rate, over 5 min) was used to separate the pep-
tides and direct them to an electrospray ionization source equipped on an LTQ-FTICR mass spectrometer (Thermo Fisher Scientific,
Santa Clara, CA). Valves, columns, and tubing for protein digestion and peptide separation were immersed in an ice-water bath to
minimize back-exchange.
To map the peptic peptides, the digest, in the absence of HDX, was submitted to bottom-up proteomics analysis by liquid chro-
matography-tandem mass spectrometry (LC-MS/MS) with the LTQ-FTICR mass spectrometer. Digestion conditions (denaturant
concentration in quench buffer) were optimized under ‘‘HDX assay’’ conditions with the absence of D2O. The peptic peptides
were identified using Byonic and Byologic (Protein Metrics, Cupertino, CA). The peptide sets and raw HDX data were then submitted
to HDExaminer (Sierra Analytics, Modesto, CA) for deuterium uptake calculation and data visualization in automated fashion with
manual validation. Peptides for each run were assessed based on relative representation and statistical validation. The deuterium
uptake at each time point was calculated by subtracting the centroid of the isotopic distribution of the non-deuterated peptide
from that of the deuterated peptide. The relative deuterium uptake was plotted versus the labeling time to yield kinetic curves.
Native Mass Spectrometry
SFTSV L 1-231 aa was buffer exchanged to 150 mM ammonium acetate, pH = 6.8 with the Bio-Spin 6 Columns (Bio-Rad, Hercules,
CA). Samples containing 2.5 mMSFTSV L or 2.5 mMSFTSV L plus 100 mMMnCl2 in the ammonium acetate buffer were loaded into the
ES380 borosilicate nanoES spray emitters (Thermo Fisher Scientific, Santa Clara, CA). The emitters were mounted on the Exactive
Plus EMR mass spectrometer (Thermo Fisher Scientific, Santa Clara, CA) to acquire mass spectra for 1 to 2 min. Some MS param-
eters are: 1.5 kV spray voltage, 20 eV in-source CID, 20 HCD cell energy, 100C transfer capillary temperature. All assays performed
at least in triplicate using at least two different protein preparations.
Molecular Dynamics Simulations
Molecular dynamics simulations were run with Gromacs 5.1.1 at 300 K using the AMBER03 force field with explicit TIP3P solvent
(Abraham et al., 2015; Duan et al., 2003; Jorgensen et al., 1983). Simulations were prepared by placing the starting structure
(PDB ID: 6NTV) in a dodecahedron box that extends 1.0 A˚ beyond the protein in any dimension. The system was then solvated
(32770 atoms), and energy minimized with a steepest descents algorithm until the maximum force fell below 100 kJ/mol/nm using
a step size of 0.01 nm and a cutoff distance of 1.2 nm for the neighbor list, Coulomb interactions, and van der Waals interactions.
For production runs, all bonds were constrained with the LINCS algorithm and virtual sites were used to allow a 4 fs time step (Feen-
stra et al., 1999; Hess, 2008). Cutoffs of 1.0 nmwere used for the neighbor list, Coulomb interactions, and van der Waals interactions.
The Verlet cutoff scheme was used for the neighbor list. The stochastic velocity rescaling (v-rescale) (Bussi et al., 2007) thermostat
was used to hold the temperature at 300 K. Conformations were stored every 20 ps.
The FAST algorithm (Zimmerman and Bowman, 2015, 2016) was used to enhance conformational sampling of the C-terminal helix
(residues 209-226) when generating simulation data. FAST-distance simulations were run for 8 rounds, with 10 simulations per round,
where each simulation was 40 ns in length (3.2 ms aggregate simulation). The FAST-distance ranking function favored restarting sim-
ulations from states thatmaximized pairwise distances between heavy-atoms on theC-terminal helix and their initial neighbors. Addi-
tionally, a similarity penalty was added to the ranking to promote conformational diversity in starting structures, as has been
described previously (Zimmerman et al., 2017).
A Markov state model (MSM) was built from the FAST simulation data using enspara (https://github.com/bowman-lab/enspara).
AnMSM is a network representation of a free-energy landscape, where nodes are discrete conformational states and directed edges
are conditional transition probabilities. The state space was defined using backbone heavy atoms (atoms C, Ca, Cb, N, O), which was
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clustered with a k-centers algorithm based on RMSD between conformations until every cluster center had a radius less than 1.8 A˚.
Then 10 sweeps of a k-medoids update step was used to center the clusters on the densest regions of conformational space.
Following clustering, an MSM was built by row-normalizing the observed transition counts, at a lag-time of 2 ns, with a small
pseudo-count as a prior (Zimmerman et al., 2018). Radius of gyration and the solvent accessible surface areas for each state in
the MSMwere calculated using MDTraj and were weighted based on their determined populations (McGibbon et al., 2015). The sol-
vent accessible surface area (SASA) of each residue was averagedwith the preceding and subsequent residue to highlight concerted
behaviors.
Surflex-Docking of BXA and L-742,001 to SFTSV L
The crystal structure of SFTSV L does not contain Mn2+ metal atoms, which are necessary for BXA and L-742,001 binding. Protein
structures containing Mn2+ used for docking were generated by aligning the SFTSV L crystal structure (PDB 6NTV) to that of IAV
H1N1 PA in complex with DPBA (PDB 4AWF) (Kowalinski et al., 2012) and using the resulting positions of the two Mn2+ metal atoms.
The alignment was achieved using SFTSV L residues 112-130 to IAV H1N1 PA residues 108-123; this resulted in a good alignment of
active site residues His80, Asp112, Glu126 and Phe127 that are critical for binding Mn2+.
MOL2 files for BXA and L-742,001 were generated using Open Babel (O’Boyle et al., 2011) and docked to the PDB files described
above using Surflex-dock (Jain, 2007). Specifically, a threshold of 0.25 and bloat of 2.0 were used to generate the receptor protomols,
and the default ‘-pgeom’ docking parameters were used to dock the compounds. To ensure that the 2,4-dioxobutanoic acid in BXA
and L-742,001 were coordinated properly, we performed a fragmet-guided search using a 20 pKd/A˚
2 deviation penalty (Jain, 2007).
The reference 2,4-dioxobutanoic acid fragment was created from the structure alignment to PDB 4AWF described above, with the
phenyl ring removed. Active site residues important for binding were defined as His80, Asp112, Glu126, Phe127, Ser128, Lys145,
Glu219, and Ala223.
Virus Growth Inhibition Assay
Confluent monolayers of Vero E6 cells in 24-well plates were washed once with DMEM and infected with either SFTSV or HRTV at
0.01 MOI. The plates were placed on a rocker in 37C incubator for 1 hr for virus adsorption. The virus inoculum was removed and
replaced by DMEMmedium containing BXA or L-742,001 at various concentrations and incubated at 37C in 5% CO2. Viruses were
harvested every 24 hr until day 5 post-infection, and the virus yield was visualized by immunostaining and expressed as TCID50/ml
using Reed–Muench method. Briefly, after infecting the virus samples in quadruplicate and incubated at 37C in 5% CO2 for 3 days,
Vero E6 cells in 96-well plate were fixed with 4% (w/v) paraformaldehyde (PFA) for 20 min at room temperature (RT). PFA-fixed cells
were treated with 0.25% (v/v) Triton X-100 for 20 min at RT. Virus-infected cells were detected by probing with either Anti-NP (Sun
et al., 2014) (pAB, for SFTSV) or 2AG8 (Calvert and Brault, 2015) (mAb, for HRTV) prepared in blocking buffer: DPBS containing 5%
FBS for 1 hr at 37C, followed by anti-rabbit Alexa Fluor 488 (for Anti-NP) or anti-mouse Alexa Fluor 488 (for 2AG8) (Thermo Fisher
Scientific, USA) prepared in blocking buffer for 30 min at 37C. Two washing cycles of DPBS was done after each step of the immu-
nostaining. After the final washing, the cells were then visualized, and the virus infection were detected using Keyence BZ-X710 fluo-
rescence microscope. As a control, the infected cells incubated in BXA-free medium were included throughout the experiment.
Plaque Reduction Assay
Confluent monolayers of Vero E6 cells in 6-well plates werewashed oncewith DMEMand infectedwith either about 100 pfu of SFTSV
or HRTV. The plates were placed on a rocker in 37C incubator for 1 hr for virus adsorption. The virus inoculum was removed and
replaced by overlay media (DMEM containing 1% low-melting agarose, without serum), containing BXA at various concentrations.
After incubating cultures in 37C incubator with 5% CO2, until plaques can be visualized under light, monolayers were fixed with 4%
formaldehyde solution for 30 min and the agarose was then removed by flowing water and stained with 0.2% (w/v) crystal violet so-
lution. The plaques were counted by visual examination and the required concentration to reduce the 50% plaque number (EC50),
was calculated as relative to the control without BXA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n with the description of what n represents, the mean and the SEM are reported in
Figures 1, 2, 3, 4, 5, and 6 and their legends. Statistical analyses were performed using Origin (OriginLab).
DATA AND CODE AVAILABILITY
The hydrogen deuterium exchange mass spectrometry plots are available at https://data.mendeley.com/datasets/f5t9tdvn5n/1.
Protein Data Bank (PDB; https://www.rcsb.org/): 6NTV.
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ANDV_L M                                                                                                    E V VS E D L L A HD IKYREIHQR RDLAPGT AL CI......................... L....................... DR Y VR LVDQM KHDWSDNKD
IAV_PA M                                                                                                    E L E A I H MDFVRQCFNPMIV...E AEKAMK......................... Y.....GE.......DP...KIETNKF A CT .LEVCF YSDGGSKHR
UUKV_L M                                                                                                    I LN D A HDLLAI.CSRT RQQ...G CPPAVTFTSSHMRPPIPSFLLWTEGSDVLM FDLDTIPAGSVTGSSIGP.KFKIKTQA SSFV FTFAHWCDA......
SEOV_L M                                                                                                    E L LT E D L L A HD IKYREIHRD KEFTINS AV CM......................... Y....................... DR Y VR IVDQM KHEWSDNKD
SNV_L  M                                                                                                    E V AS E D L L A HD IKYREIHQR KEIPPGG AL CL......................... L....................... DR Y VR VVDQM KHDWSDNKD
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HRTV_L                                                     PD                                              D V P MT  RL GT V IE T T Y L ET RKL......SE F.................. LV.....H...DGSDS VIHT D . VV F T .RSTNMGGLEA..A RSK ... KYRD
TOSV_L                                                     PD                                              D V G S  G V VE T T IT KKF......VE F.................. VL.....ENRADDSDFQ MIIETET H. YV F T .MGDANSAD.L..AARNK ...AKYEI
LACV_L                                                     PD                                              I P IT  I L ID S DLNIEYRNDVPFID ILD..........IRPEVD LT.....I....DAPH NYL.Y NNV. YI YKV .VSNESSVI........TY... KYYE
LASV_L                                                     PD                                              E V   KL GN L LE Y ES DKS.......VER..................ILHDHGILT...PSLCF V GY.. T V IL CFVR.SSPA.NFE...QK IEDFKKL Q...
ANDV_L                                                     PD                                              E V P MT  KI GN I IE T T Y L EV RPI......GQ LLMAGIPNDIIQGMEKKII NSPSGQVL...KSFFR NY.. T L EF V V .ADVSRGIREKKIA EGG QFV HLLE
IAV_PA                                                     PD                                              E   N IE T Y AF IIE......GRDRIMAWTVVNS.........ICNTTGVE......KPKFL LY..DYKE ..RF IGV RREVH.......IY LEK NKIKS...
UUKV_L                                                     PD                                              D P T  RL GS VE T N F VS MPL......RDHF.................. LV.....N...DTFDHW FISQ D .KVV F T .RSDQEQSLIS..A NTK ...GKYEV
SEOV_L                                                     PD                                              E V P MT  RI GS I VE T T Y L ES EPI......SK LLFAGIPNNVITALEKKVI DHPSGKTL...RSFFK NY.. T L EF V V .ADVDKGIREKKMK ELG KYL QELM
SNV_L                                                      PD                                              E V P MT  KI G I IE T T Y L EM RPI......GQ LLMAGVPNDVIQGMEKKVI TSPSGQIL...KSFFR NY.. T AL EF V V .ADVAKGIREKKLK ESG QFV SLLS
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SFTSV_L     R  I     V   VIVV    G   N        E      R   A   Y       M           E                          PISR VD MENPR FFG    .SSG VLS ..MPLTQD AEELMY FCI NEI TKARS.. DADIELQKSEE .LEAISRALSFF..........
HRTV_L     R  I     I   IIVV    G   N        E      R   A   Y       M           E                          PLNR SD MPDAS YFG    .SAS VLT ..MPLTQD AEELMF FCV NEI SQARA.. DAEVELQKSEE .YEAISRARAFF..........
TOSV_L     R        I   IIAV    G   N        E      R   A   F       I                                      ACLD SA...IKP SLY    .HFN VVS ..LDLSDE VNEIVF FRL RDI EELRE.. N...................PALF..D.......
LACV_L        I     I   IVII    P                       V   F       L           E                          L...TRD SDRLS PIE    .RID VSRD..LHINSDRFKELYPTIV. DIN NQFFD.. KQLLYEKFGDD .EFLLKV.......A.......
LASV_L     K  L     V   LI L        N                                           E                          ...L ED K...T NIS  P IDGRTSFY EQIPDWV..............NDKLRDTL..FSLLR....YAQ ........S.............
ANDV_L     K  I     I   VVAV    G   S        D      R   A   Y       I                                      TESR GN PQPYK TFS    .KTD SNI TQWPSRRN GVIQHM LVQ DIN VREHL.. .................................K
IAV_PA     K            I                           R   I                       E                          ...E ........THIH FSF.TGEEMATKADYTLDEESRARIKT LFT RQEMASRSL..WDSFRQSERAAA LA...LVPR.............
UUKV_L     R        I   VVVV        N        E      R   A           I           D                          ALHN ST...TSS LFG    .SETTVVT ..LNLNQQ VDELCF FLV RAVHLEMTTKM I..PEYDDEDE .KRSREVKAAFHSVQ.......
SEOV_L     R  L     I   VVAV    G   S        D      R   A   Y       V           E                          TFFH GE QNPYK TFK    .RTD SNI TQWPSARN GVVQYM LVQ EIS VREHL.. KT...EERAAL AMFNLKFNISSLKTQPYFIPEY
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Figure S1. Sequence analysis of SFTSV and bunyaviruses. Related to Fig 1 and 2. (A) Domain organization of SFTSV L 
protein sequence used in the current study. (B) A phylogenic tree of bunyaviruses and arthomyxociruses was performed by 
aligning the full L protein sequence using Geneious Prime software (Geneious Prime 2019.2). (C) Structure-based sequence 
alignment of endonuclease domains show high sequence conservation. Details in the STAR Methods. 





















Figure S2.  Native mass spectrometry anaysis. Related to Fig 1. Intact mass measurement of a SFTSV L 1-231 aa crystal 
using LC/MS. Deconvoluted mass spectrum of SFTSV L 1-231 aa during cystalization screening (no Se-Met). Determined 
mass of the crystal by LC-MS was 25143 Da. The theoretical mass for SFTSV L 1-226 aa is 25143 Da, suggesting that the 
Met-His6-tag and SFTSV L residues 227-231 were cleaved by trypsin. The 26893 Da species is the His6-tagged SFTSV L 1-
226 aa with methionine cleaved. The 27071 Da is Met-His6-tagged SFTSV L 1-226 aa with a +46 Da modification on the first 
methionine.  























Figure S3. FRET-based endonuclease assay curves with different ions. Related to Fig 3. FRET-based experiments are 
shown for endonuclease reactions of SFTSV L 1-231 aa with 1 mM MnCl2 (blue), 1 mM MgCl2 (magenta), 5 mM MgCl2 (dark 
yellow), 10 mM MgCl2 (orange), 20 mM MgCl2 (cyan), 1 mM CaCl2 (olive) and no ions (red). Buffer only (black) was included 
as a control. Experiments were carried out in triplicate and average data are shown with error bars representing the standard 
deviation. 
(A) (B)
Figure S4. The surface β-sheet region is predicted to be associated with protein-protein interactions. Related to Fig 2. 
(A) Electrostatic representation of the SFTSV endonuclease domain. (B) Residues (colored in blue) within the surface β-sheet 
region are predicted to be associated with protein-protein interactions. The surface β-sheet region is outlined with the box. 
















 times  (10  s,  30  s,  60  s,  120  s,  900  s,  3,600  s  and  14,400  s)   are  mapped  using  color  
gradient shown below, where cooler colors represent regions with lower percentages of deuterium uptake and warmer colors 
represent regions with higher percentages of deuterium uptake. Data shown are the average of duplicate samples. 
(A) (B)
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Figure S6. Enzyme inhibition assay and Virus growth inhibition assay of SFTSV, HRTV and Influenza virus. Related 
to Fig 5. (A) Endonuclease inhibition was measured for SFTSV L 1-231 aa (black), HRTV L 1-231 aa (red), or IAV PA 1-192 
aa (blue) in presence of difference concentrations of L-742,001. Fluorescence values were expressed as percentages of non-
treated controls, and EC50 (50% effective concentration) values of the test compound were determined. Cell cultures were used 
to determine the virus growth properties. (B) SFTSV or (C) HRTV was infected at a MOI of 0.01 in Vero E6 cells with different 
concentrations of L-742,001 (100 µM, black; 50 µM, red; 25 µM, blue; 12.5 µM, orange; 0 µM, cyan) in quintuplicate. Cultures 
were collected every 24 hrs and subjected to plaque assay. (D) Docking simulation of two Manganese ions (purple) and L-
742,001 (cyan) with SFTSV L 1-231 aa (green). 
Table S1. RMSD pairwise values, and number of equivalent positions in parenthesis, calculated from pairwise structural 
alignments using Superpose with the endonucleases used in this study: TOSV (6QW5), LACV (2XI5), LASV (5J1P), ANDV 
(5HSB) and Influenza A virus (5DES) and SFTSV L endonuclease structures. The molecule in the asymmetric unit used in the 
alignment is indicated in parenthesis for each PDB. Related to Fig 2. 
 TOSV(A) LACV(A) LASV(A) ANDV(A) IAV(A) 
SFTSV(A) 
1.93 Å (177 
residues) 
3.12 Å (94 
residues) 
2.87 Å (107 
residues) 
2.84 Å (117 
residues) 
3.46 Å (102 
residues) 
 




SFTSV L 1-231 aa 2.1 ± 0.2 0.14 ± 0.005 
HRTV L 1-231 aa 3.3 ± 0.4 0.12 ± 0.002 
IAV PA 1-192 aa 1.4 ± 0.1 0.036 ± 0.003 
 
Table S3. Data collection and refinement statistics. Related to Fig 1. 
 Se-Met SFTSV L 1-231 Se-Met SFTSV L 1-231 
Data collection 
Wavelength 0.9792 0.9792 
Resolution range 46.63-2.50 (2.59-2.50) 47.09 - 2.40 (2.49 - 2.40) 
Space group P43212 P43212 
Unit cell   
a, b, c (Å) 83.0 83.0 230.2 82.7 82.7 229.1 
α, β, γ (°) 90 90 90 90 90 90 
Total reflections 366112 (36068) 247530 (24903) 
Unique reflections 53114 (4471) 32031 (2936) 
Multiplicity 6.9 (6.8) 7.7 (8.0) 
Completeness (%) 97.91 (84.36) 98.90 (93.83) 
Mean I/sigma(I) 10.86 (2.72) 14.02 (4.10) 
Wilson B-factor 35.72 36.39 
R-merge 0.2193 (1.527) 0.1225 (0.7682) 
R-meas 0.2373 (1.655) 0.1316 (0.8235) 
R-pim 0.09017 (0.6331) 0.04736 (0.2938) 
CC1/2 0.991 (0.520) 0.997 (0.798) 
CC* 0.998 (0.827) 0.999 (0.942) 
Phase determination, structure solution, and refinement 
Anomalous scatterer Selenium (18 sites)  
Figure of merit 0.306  
Reflections used in refinement 52027 (4471) 31736 (2936) 
Reflections used for R-free 2488 (220) 2000 (185) 
R-work 0.3025 (0.3400) 0.2005 (0.2448) 
R-free 0.3653 (0.4006) 0.2380 (0.2857) 
CC(work)  0.955 (0.845) 
CC(free)  0.927 (0.815) 
Number of non-hydrogen atoms  5419 
macromolecules  5229 
solvent  190 
Protein residues  678 
RMS(bonds)  0.006 
RMS(angles)  1.21 
Ramachandran favored (%)  97.92 
Ramachandran allowed (%)  2.08 
Ramachandran outliers (%)  0.00 
Rotamer outliers (%)  0.00 
Clashscore  6.27 
MolProbity Score  1.36 
Average B-factor  42.30 
macromolecules  42.39 
solvent  39.75 
PDB ID  6NTV 
 
